WO2014011971A3 - Deuterated carfilzomib - Google Patents

Deuterated carfilzomib Download PDF

Info

Publication number
WO2014011971A3
WO2014011971A3 PCT/US2013/050241 US2013050241W WO2014011971A3 WO 2014011971 A3 WO2014011971 A3 WO 2014011971A3 US 2013050241 W US2013050241 W US 2013050241W WO 2014011971 A3 WO2014011971 A3 WO 2014011971A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
carfilzomib
deuterated
compound
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/050241
Other languages
French (fr)
Other versions
WO2014011971A2 (en
Inventor
Adam Morgan
Roger Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Priority to EP13816478.5A priority Critical patent/EP2872159A2/en
Priority to US14/414,504 priority patent/US20150166601A1/en
Publication of WO2014011971A2 publication Critical patent/WO2014011971A2/en
Anticipated expiration legal-status Critical
Publication of WO2014011971A3 publication Critical patent/WO2014011971A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention in one embodiment provides a compound of Formula 1 (structurally represented), or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification. The compound of Formula I is useful for the treatment of diseases such as a disease selected from the group consisting of multiple myeloma, solid tumors, lymphoma, and leukemia.
PCT/US2013/050241 2012-07-13 2013-07-12 Deuterated carfilzomib Ceased WO2014011971A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13816478.5A EP2872159A2 (en) 2012-07-13 2013-07-12 Deuterated carfilzomib
US14/414,504 US20150166601A1 (en) 2012-07-13 2013-07-12 Deuterated carfilzomib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671448P 2012-07-13 2012-07-13
US61/671,448 2012-07-13

Publications (2)

Publication Number Publication Date
WO2014011971A2 WO2014011971A2 (en) 2014-01-16
WO2014011971A3 true WO2014011971A3 (en) 2015-07-23

Family

ID=49916696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/050241 Ceased WO2014011971A2 (en) 2012-07-13 2013-07-12 Deuterated carfilzomib

Country Status (3)

Country Link
US (1) US20150166601A1 (en)
EP (1) EP2872159A2 (en)
WO (1) WO2014011971A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088031A1 (en) * 2014-12-02 2016-06-09 Fresenius Kabi Oncology Limited A process for purification of carfilzomib
CN105294501B (en) * 2015-08-21 2017-09-29 上海应用技术学院 A kind of preparation method of Carfilzomib midbody compound
JP6802899B2 (en) * 2016-07-25 2020-12-23 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． Substituted boronic acid compounds, pharmaceutical compositions containing the compounds and their use
CN108473487B (en) 2016-12-13 2021-08-03 普林斯顿药物研发公司 a protein kinase inhibitor
CN108794516A (en) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 Boric acid and boric acid ester compound and its preparation method and application
WO2018213263A1 (en) * 2017-05-15 2018-11-22 The Regents Of The University Of California Immunoproteasome inhibitor
CN107556246A (en) * 2017-09-26 2018-01-09 中国科学院青岛生物能源与过程研究所 Imidazoleimines class part, its iron/cobalt complex and its application in polyisoprene synthesis
CN109053861A (en) * 2018-09-29 2018-12-21 上海雅本化学有限公司 A kind of preparation method of Carfilzomib
US20250281449A1 (en) * 2021-05-05 2025-09-11 Centre National De La Recherche Scientifique Nitrogen-containing analogs of salinomycin for use in multiple myeloma (mm)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131421A1 (en) * 2004-04-15 2009-05-21 Smyth Mark S Compounds for proteasome enzyme inhibition
US20110236428A1 (en) * 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US20130109017A1 (en) * 2010-11-12 2013-05-02 University Of Utah Research Foundation Multiple myeloma prognosis and treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131421A1 (en) * 2004-04-15 2009-05-21 Smyth Mark S Compounds for proteasome enzyme inhibition
US20110236428A1 (en) * 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US20130109017A1 (en) * 2010-11-12 2013-05-02 University Of Utah Research Foundation Multiple myeloma prognosis and treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CREWS LABORATORY: "Carfilzomib/Kyprolis: The Next Generation Proteasome Inhibitor Drug.", CREWS LABORATORY AT YALE UNIVERSITY [DATA SHEET, 24 September 2011 (2011-09-24), XP008179661, Retrieved from the Internet <URL:http://crewslab.yale.edu/researchlcarfilzomib-kyprolis> [retrieved on 20131126] *
DEMO, SD ET AL.: "Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome", CANCER RES, vol. 67, 1 July 2007 (2007-07-01), pages 6383 - 6391, XP002503827 *
KUHN, DJ ET AL.: "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma", BLOOD, vol. 110, 5 June 2007 (2007-06-05), pages 3281 - 3290, XP002679911 *
O'CONNOR, OA ET AL.: "A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies", CLIN CANCER RES, vol. 15, 10 November 2009 (2009-11-10), pages 7085 - 7091, XP055261218 *
WANG, Z ET AL.: "Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib.", DRUG METAB DISPOS, vol. 41, January 2013 (2013-01-01), XP055261170 *

Also Published As

Publication number Publication date
US20150166601A1 (en) 2015-06-18
EP2872159A2 (en) 2015-05-20
WO2014011971A2 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
PH12019500480A1 (en) Pyridine compound
MX2013011589A (en) Methods and compositions for treating parkinson&#39;s disease.
MX2015002040A (en) Deuterated baricitinib.
HK1215579A1 (en) Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
WO2014052563A3 (en) Novel compounds that are erk inhibitors
MX2015001246A (en) Deuterated ibrutinib.
MX2013011591A (en) Methods and compositions for treating neurodegenerative diseases.
MX367618B (en) Substituted benzofuranyl and benzoxazolyl compounds and uses thereof.
SA518400493B1 (en) Carfilzomib compounds treated with polyethylene glycol
WO2016011390A8 (en) Irak4 inhibiting agents
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
HK1255500A1 (en) Oxysterols and methods of use thereof
EP4599887A8 (en) Oxysterols and methods of use thereof
MX2015008829A (en) Deuterated momelotinib.
TN2017000031A1 (en) Imidazopyridazine compounds
WO2014179567A3 (en) Methods and compositions for treating beta-thalassemia and sickle cell disease
WO2013109972A3 (en) Therapeutic compounds
WO2013040227A3 (en) Therapeutic compounds
WO2015042414A8 (en) Multicyclic compounds and methods of using same
MX2013007937A (en) Novel indole or indazole derivative or salt thereof.
WO2018039077A8 (en) Therapeutic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816478

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14414504

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2013816478

Country of ref document: EP